Foghorn Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
18.8%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$1.06next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly183.6MTarget: Sufficient to fund operations into the first half of 2028
Collaboration Revenue Quarterly3.3M
Research and Development (R&D) Expenses Quarterly18.3M
Watch Items
- FHD-909 Phase 1 Dose-Escalation DataTrigger: Topline Phase 1 dose-escalation data and go/no-go decision on dose-expansion expected mid-2026Action: Evaluate clinical efficacy and safety profile in SMARCA4-mutant solid tumors (primarily NSCLC) to determine progression to Phase 1b expansion cohorts with Eli Lilly.
- Selective CBP Degrader IND-Enabling StudiesTrigger: Completion of IND-enabling studies in 2026 and IND filing expected in 2027Action: Monitor progression of CBPd-171 preclinical toxicology and formulation optimization for ER+ breast cancer.
- Selective EP300 Degrader IND-Enabling StudiesTrigger: Completion of IND-enabling studies in 2026 and IND filing expected in 2027Action: Track preclinical safety and efficacy data in multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL).
- Selective ARID1B Degrader ProgramTrigger: Advancing towards in vivo proof of concept in 2026Action: Assess selective degradation of ARID1B and downstream target gene modulation in ARID1A-mutant solid tumors.
Research as of 20 Jun 2026